AMRI Announces Albuquerque, N.M. Manufacturing Facility Fully Operational
News Nov 28, 2014
AMRI has announced that its Albuquerque, N.M. sterile injectable facility has resumed full manufacturing operations. As previously announced, in September 2014 AMRI identified an environmental deviation in one manufacturing suite as a result of a weather related business interruption. The resulting remediation has now been completed.
Commenting on its operations, William S. Marth, AMRI's President and Chief Executive Officer, said: "We are pleased to report that all suites at our OsoBio Albuquerque aseptic manufacturing facility are fully operational. I would like to acknowledge and thank our colleagues and vendors for their dedicated efforts in remediating the affected manufacturing suite as quickly as possible."
AMRI's OsoBio facility is an established provider of cGMP manufacturing and sterile filling of parenteral drugs using specialized technologies, including lyophilization.
With its cGMP aseptic filling expertise, OsoBio supports commercial scale production of liquid-filled and lyophilized parenterals.
These services are provided for both small molecule drug products as well as biologicals. Oso Biopharmaceutical Manufacturing was acquired by AMRI in July 2014.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019